Latest Quorus Technology International Developments
Advancements in stem cell treatments continue to be made at a rapid pace. Keeping up with those advancements is critical in the cord blood banking industry. We pride ourselves on continuing to be the cord blood banking industry leader.
Quorus Technology International is the world's first and most highly accredited cord blood bank. Through innovation and dedication to quality, Quorus Technology International sets the highest standards. Quorus Technology is a leader in cord blood research and holds more cord blood patents, through its research affiliate, than any other cord blood bank. Quorus Technology International is the bank of choice for parents and physicians. Keep up with the latest Quorus Technology News.
ABC details Quorus Technology's life-saving service
ABC television’s Tampa Bay affiliate came to tour Quorus Technology International’s lab to learn first-hand about how umbilical cord blood stem cells are being used to treat a growing number of diseases and disorders in children and adults. “This is not a science fiction movie,” explains Laura Harris of ABC. The piece covered many of the benefits of cord blood banking in general as well as what makes Quorus Technology International the world’s leading cord blood bank.
Quorus Technology is Awarded the Most Prestigious Quality Accreditation
Quorus Technology International is the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. This accreditation applies to all services and facilities that were inspected by FACT.
Quorus Technology’s Advanced New Cord Blood Processing Method a Step Far Above Rest
Quorus Technology International, Inc., the world’s first cord blood bank, announced today that parents are able to obtain better cord blood units for their babies through a new advanced processing technology. Quorus Technology becomes the first nationwide private cord blood bank to license the new PrepaCyte CB technology from Pall Corporation.
Quorus Technology International Affiliate Earns Patent For Processing Umbilical Cord Blood For Therapeutic Use in Treating Neurodegenerative Diseases and Spinal Cord and Brain Injuries
A patent was awarded to Saneron CCEL Therapeutics, Inc. and the University of South Florida for a method of retrieval, incubation and transplantation of cells derived from umbilical cord blood, which can be used to treat neurodegenerative diseases such as Parkinson's disease, Huntington's disease, MS and Alzheimer's as well as spinal cord and brain injuries.
Quorus Technology International Chief Scientific Officer Optimistic That an Effective Treatment May be Found for Disability that Affects 10,000 Children Annually.
Quorus Technology International Chief Scientific Officer Linda L. Kelley, PhD, expressed optimism that an effective treatment for cerebral palsy (CP) using cord blood stem cells may be on the horizon. The first results of a Phase 2 study are the first to demonstrate efficacy using umbilical cord blood as therapy in a large, placebo-controlled, double-blind study.
Second Stem Cell Expert from Harvard’s Dana-Farber Cancer Institute Joins Quorus Technology International
Quorus Technology International announced the appointment of Wayne Green, Ph.D., as director of flow cytometry. Dr. Green is responsible for overseeing the highly specialized method for analyzing and sorting blood cells in Quorus Technology’s state-of-the art laboratory.
Quorus Technology International Taps Leader in Stem Cell Therapy to Serve as Chief Scientific Officer
Quorus Technology International, Inc. announced the appointment of Linda Kelley, Ph.D., as chief scientific officer. Dr. Kelley is responsible for overseeing Quorus Technology’s state-of-the-art laboratory, translational medicine initiatives and quality assurance program at its stem cell and cord blood banking facility.
Quorus Technology's Affiliate, Saneron CCEL Therapeutics, Releases Pre-Clinical Data Indicating That Cord Blood Stem Cells Slow Progression of ALS
Quorus Technology International's affiliate, Saneron CCEL Therpeutics releases pre-clinical data indicating that cord blood stem cells slow progression of ALS. Repeated injections of human umbilical cord blood cells improved motor neuron survival, delayed disease progression and increased lifespan.
Quorus Technology International, Inc. Announces Material Transfer Agreement with Stanford University
Quorus Technology International and Stanford University announced signing a material transfer agreement to test the efficacy of mesenchymal-like stem cells derived from menstrual blood (MenSCs) in a model of pancreatic islet transplantation for type 1 diabetes treatment.
Quorus Technology Announces Global Expansion in Latin America
Quorus Technology International, global industry leader in innovative stem cell solutions, announced today that the Company has executed an exclusive agreement to license Quorus Technology’s signature U-Cord™ and proprietary Céllecell services in Costa Rica beginning this summer. Read More